32255-79-1

Upstream product

• 38879-47-9 (Z)-4-(3,4-dimethoxybenzylidene)-2-methyl-5(4H)-oxazolone 
• 143815-52-5 (Z)-3-(3,4-dimethoxyphenyl)-2-hydroxyacrylic acid 
• 676626-91-8 (Z)-4-(3,4-dimethoxybenzylidene)-2-methyloxazol-5 (4H)-one 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 2859-78-1 4-Bromoveratrole 
• 115005-76-0 (2R)-oxirane-2-carboxylic acid 
• 143815-52-5 (Z)-3-(3,4-Dimethoxy-phenyl)-2-hydroxy-acrylic acid 
• 10040-91-2 5-(3,4-di-methoxybenzylidene)imidazolidine-2,4-dione 
• 39829-15-7 methyl 3-(3,4-dimethoxyphenyl)oxirane-2-carboxylate 
• 76313-28-5 2-acetylamino-3-(3,4-dimethoxy-1-phenyl)-2-propenoic acid 
• 54814-41-4 (+/-)-(R)-methyl 3-(3,4-dimethoxyphenyl)-2-hydroxypropanoate 

Downstream Products

• 1322088-10-7 allyl 3-(3,4-dimethoxyphenyl)-2-hydroxypropanoate 
• 54814-41-4 (+/-)-(R)-methyl 3-(3,4-dimethoxyphenyl)-2-hydroxypropanoate 
• 179462-74-9 rosmarinic acid 
• 1403877-29-1 C₂₀H₂₀O₆ 
• 1430417-55-2 (E)-1-(allyloxy)-3-(3,4-dimethoxyphenyl)-1-oxopropan-2-yl 3-(3,4-dihydroxyphenyl)acrylate 
• 1403877-28-0 C₂₈H₂₈O₇ 
• 1430417-23-4 (E)-1-(allyloxy)-3-(3,4-dimethoxyphenyl)-1-oxopropan-2-yl 3-(3,4-bis(tert-butyldimethylsilyloxy)phenyl)acrylate 
• 1430417-21-2 (E)-1-(allyloxy)-3-(3,4-dimethoxyphenyl)-1-oxopropan-2-yl 3-(2,3-dihydrobenzofuran-6-yl)acrylate 
• 1430417-19-8 (E)-1-(allyloxy)-3-(3,4-dimethoxyphenyl)-1-oxopropan-2-yl 3-(naphthalen-2-yl)acrylate 
• 1403877-27-9 (E)-1-(allyloxy)-3-(3,4-dimethoxyphenyl)-1-oxopropan-2-yl 3-(3,4-bis(benzyloxy)phenyl)acrylate 
• 1322088-12-9 (E)-1-(allyloxy)-3-(3,4-dimethoxyphenyl)-1-oxopropan-2-yl 3-(3,4-dimethoxyphenyl)acrylate 
• 1430417-15-4 (E)-1-(allyloxy)-3-(3,4-dimethoxyphenyl)-1-oxopropan-2-yl 3-(4-methoxyphenyl)acrylate 
• 1403877-26-8 (E)-1-(allyloxy)-3-(3,4-dimethoxyphenyl)-1-oxopropan-2-yl 3-(4-(benzyloxy)phenyl)acrylate 
• 1430417-12-1 (E)-1-(allyloxy)-3-(3,4-dimethoxyphenyl)-1-oxopropan-2-yl 3-(4-phenylphenyl)acrylate 

Relevant academic research and scientific papers

TRPV4 activity inhibitor

PROBLEM TO BE SOLVED: To provide a compound that inhibits TRPV4 activity and is useful for prevention or improvement of overactive bladder and irritable bowel syndrome or the like. SOLUTION: A TRPV4 activity inhibitor has a rosmarinic acid derivative selected from the formulae (Ia)-(Id) or a salt thereof as an active ingredient. SELECTED DRAWING: None COPYRIGHT: (C)2020,JPOandINPIT

The asymmetric total synthesis of (+)-salvianolic acid A

An asymmetric synthesis of (+)-salvianolic acid A with cardioprotective properties, has been accomplished in a convergent manner in eight steps and 10.6% overall yield. This synthesis features an asymmetric addition of organometallics to optically pure 2,3-epoxypropionate in the presence of BF3·Et2O, Ru(III)-catalyzed directed [Formula presented] olefination, and I2-catalyzed isomerization reaction.

Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1)

A series of MMP-1 inhibitors have been identified based upon a methyl rosmarinate scaffold using structure-based drug design methods. The best compound in the series showed an IC50 value of 0.4 μM. A docking study was conducted for compound (S)

A modified synthesis of (±)-β-aryllactic acids

The synthesis of racemic forms of the reportedly active principle of Danshen, namely (±)-β-(3,4-dihydroxyphenyl)lactic acid [(±)3-(3,4-dihydroxyphenyl)-2-hydroxypropanoic acid] and its seven racemic derivatives is reported.